TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks

Benzinga Logo Benzinga By Vandana Singh
Sanofi's Multiple Sclerosis Drug Faces Trial And Regulatory Setbacks

Sanofi announced its multiple sclerosis drug tolebrutinib failed to meet primary endpoint in a phase 3 trial for primary progressive multiple sclerosis, leading the company to halt regulatory registration efforts for this indication.

Insights
SNY   negative

Failed phase 3 trial for tolebrutinib in primary progressive multiple sclerosis, will not pursue regulatory registration, stock price dropped 1.77% in premarket trading